JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Statistical Consideration of Vaccine Clinical Trials
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Statistical Consideration of Vaccine Clinical Trials
Nam, Ju-Sun; Kang, Seung-Ho;
  PDF(new window)
 Abstract
Clinical vaccines studies (that include cancer prevention vaccines and therapeutic vaccines) are ongoing to improve the quality of life and lengthen the human lifespan. Recently clinical trials and research on vaccines have become more active due to the prevalence of new viruses such as the A(H1N1) virus that freighted the whole word in 2009. In this paper we will describe the statistical aspects of clinical vaccine trials and outline the current situation of domestic and international vaccine development.
 Keywords
Vaccine;clinical trials;sample size;
 Language
Korean
 Cited by
 References
1.
강승호 (2002). 정확검정들에 대한 고찰, <응용통계연구>, 15, 187-199.

2.
강승호 (2010). <신약개발에 필요한 의학통계학>, 자유아카데미.

3.
식품의약품안전청 <백신.BT정보방>, 식품의약품안전청.

4.
식품의약품안전청 (2006). <백신의 임상평가시 고려사항>, 식품의약품안전청.

5.
식품의약품안전청 (2007). <백신의 임상평가시 고려사항 2007>, 식품의약품안전청.

6.
식품의약품안전청 (2009a). <백신안전사용을 위한 핸드북>, 식품의약품안전청.

7.
식품의약품안전청 (2009b). <약무행정(허가.심사) 용어해설집>, 식품의약품안전청.

8.
한국과학기술정보연구원 (2006). <국가필수예방백신의 안정적공급을 위한 국가적 관리체계 구축>, 식품의약품안전청 연구보고서.

9.
Chan, I. S. F., Bohidar, N. R. (1998). Exact power and sample size for vaccine efficacy studies, Communi- cations in Statistics Part A-Theory Methods, 27, 1305-1322. crossref(new window)

10.
Ewell, M. (1996). Comparing methods for calculating confidence intervals for vaccine efficacy, Statistics in Medicine, 15, 2379-2392. crossref(new window)

11.
FDA (2010). Guidance for Industry Non-inferiority clinical trials, Draft guidance

12.
Gilbert, P. B. (2000). Some statistical issues in the design of HIV-1 vaccine an treatment trials, Statistical Methods in Medical Research, 9, 207-229. crossref(new window)

13.
Gilbert, P. B. (2010). Some design issues in phase 2B vs pahse 3 prevention trials for testing efficacy of products or concepts, Statistics in Medicine, 29, 1061-1071. crossref(new window)

14.
Horne, A. D., Lachenbruch, P. A., Geston, P. R. and Hsu, H. S. (2001a). Analysis of studies to evaluate immune response to combination vaccines, Clinical Infectious Disease, 33, S306-311. crossref(new window)

15.
Horne, A. D., Lachenbruch, P. A. and Goldenthal, K. L. (2001b). Intent-to-treat analysis and preventive vaccine efficacy, Vaccine, 19, 319-326.

16.
Jovanovic, B. D. and Levy, P. S. (1997). A look at the rule of three, The American Statistician, 51, 137-139. crossref(new window)

17.
Lachenbruch, P. A. (1998). Sensitivity, specificity, and vaccine efficacy, Controlled Clinical Trials, 19, 569- 574. crossref(new window)

18.
Lydia, A. F., Arciniega, J. and McVittie, L. (2001). Manufacturing issue with combining different antigens: A regulatory perspective, Clinical Infectious Diseases, 33, 351-355. crossref(new window)

19.
Miettinen, O. and Nurminen, M. (1985). Comparative analysis of two rates, Statistics in Medicine, 4, 213-226. crossref(new window)

20.
Nauta, J. (2006). Statistical analysis of influenza vaccine lot consistency studies, Journal of Biopharma- ceutical Statistics, 16, 443-452.

21.
Peduzzi, P., Donta, S. and Iwane, M. (1997). A Review of the design of vaccine efficacy trials and a proposal for the Design of the VA Cooperative study of active immunotherapy of HIV infection, Controlled Clinical Trials, 18, 397-419. crossref(new window)